Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Characterization of Gut Bacteria Associated with Depression in Humans Using Mouse Models

EF 2019-20

Résumé
"Major Depressive Disorder (MDD) afflicts 11.3% of Canadians at some point in their lives. Despite devastating social costs and an economic burden of 32.3 billion/year (for all types of depression), current antidepressants lack efficacy in many MDD patients and/or fail to confer long-term remission. Mounting evidence implicates the gut microbiota in MDD pathogenesis. Gut bacteria have been shown impact on diverse neuronal processes in the brain by altering activity of the vagus nerve, releasing neuro-active metabolites (i.e. neurotransmitters such as serotonin), and modulating the neuroimmune system. In MDD patients, the taxonomic composition of the gut microbiota, as well as its metabolic output, differs from healthy controls. The objective of this project is to investigate whether specific gut bacteria positively or negatively correlated with MDD in human patients impact on susceptibility to depression-like behavior in mouse models. To test this, we will colonize germ-free mice, which lack a gut microbiome, with a defined consortium of bacteria +/- single bacteria correlated with MDD. To determine whether bacteria modify susceptibility to depression, we will conduct behavioral tests designed to measure depression-like behavior in mice. We will then use metabolomic and metagenomic techniques to elucidate the mechanisms underlying any observed effects. Our work will provide critical insight into how manipulation of the gut microbiota may provide clinical benefit. By mechanistically defining how specific gut bacteria alter depression susceptibility, we aim to identify targets for novel MDD therapies. Such therapies may involve probiotic administration of ""anti-depressant"" bacteria, elimination of ""pro-depressive"" bacteria, and fecal microbiota transplantation (FMT)."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428762
Name
Cooke Noah C
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Gut Bacteria Associated with Depression in Humans Using Mouse Models
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anxiety; Behavioural Testing; Enteric Nervous System; Gnotobiotic; Gut-Brain Axis; Kynurenine Pathway; Major Depressive Disorder; Metabolism; Metagenomics; Microbiome
Abstract
"Major Depressive Disorder (MDD) afflicts 11.3% of Canadians at some point in their lives. Despite devastating social costs and an economic burden of 32.3 billion/year (for all types of depression), current antidepressants lack efficacy in many MDD patients and/or fail to confer long-term remission. Mounting evidence implicates the gut microbiota in MDD pathogenesis. Gut bacteria have been shown impact on diverse neuronal processes in the brain by altering activity of the vagus nerve, releasing neuro-active metabolites (i.e. neurotransmitters such as serotonin), and modulating the neuroimmune system. In MDD patients, the taxonomic composition of the gut microbiota, as well as its metabolic output, differs from healthy controls. The objective of this project is to investigate whether specific gut bacteria positively or negatively correlated with MDD in human patients impact on susceptibility to depression-like behavior in mouse models. To test this, we will colonize germ-free mice, which lack a gut microbiome, with a defined consortium of bacteria +/- single bacteria correlated with MDD. To determine whether bacteria modify susceptibility to depression, we will conduct behavioral tests designed to measure depression-like behavior in mice. We will then use metabolomic and metagenomic techniques to elucidate the mechanisms underlying any observed effects. Our work will provide critical insight into how manipulation of the gut microbiota may provide clinical benefit. By mechanistically defining how specific gut bacteria alter depression susceptibility, we aim to identify targets for novel MDD therapies. Such therapies may involve probiotic administration of ""anti-depressant"" bacteria, elimination of ""pro-depressive"" bacteria, and fecal microbiota transplantation (FMT)."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cooke, Noah C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~